Remibrutinib appeared very effective in treating moderate to severe chronic spontaneous urticaria, with a rapid onset of action and a favorable safety profile, according to a study published in The Journal of Allergy & Clinical Immunology.
These results indicate the drug’s potential as a preferred oral treatment option, Marcus Maurer, MD, PhD, professor of dermatology and allergy at Charité – Universitätsmedizin Berlin and associate director of the Allergie-Centrum-Charité in Berlin, and colleagues wrote.
“Chronic spontaneous urticaria (CSU) is a